Chikungunya

Emergex and Brazil’s IBMP Announce Clinical Development Collaboration for T Cell-Priming Immune Set-Point Candidates

Retrieved on: 
Tuesday, June 20, 2023
Vaccine, Fever, Yellow fever, Dengue fever, ANVISA, UKM Medical Molecular Biology Institute, Clinical trial, Research, Ministry, Molecular biology, Death, Ministry of Health (Saudi Arabia), Universal, IBMP, Pharmaceutical industry, Betacoronavirus, Health, Coronavirus, Brazilian, Chikungunya

Fiocruz has a strong commercial track record in the healthcare space, with expertise in the development, manufacturing, regulatory approval, and commercialization of medicines and medical diagnostics in Brazil.

Key Points: 
  • Fiocruz has a strong commercial track record in the healthcare space, with expertise in the development, manufacturing, regulatory approval, and commercialization of medicines and medical diagnostics in Brazil.
  • Both clinical trial product candidates have successfully completed Phase I+ clinical trials in Switzerland and are nearing submission and evaluation by ANVISA, the Brazilian health regulatory agency.
  • A Joint Steering Committee with representatives from both Emergex and IBMP will oversee the collaboration and commercialization of the select immunotherapies.
  • IBMP has also made an early equity investment into Emergex, which has potential for future expansion pending the completion of its ongoing due diligence process.

Bavarian Nordic Reports Data from a Phase 3 Clinical Trial of its VLP-Based Chikungunya Virus Vaccine in Adults ≥65 Years of Age

Retrieved on: 
Tuesday, June 20, 2023
VLP, OMX, Bavarian Nordic, Vaccination, Chikungunya, Safety, CHIKV, Vaccine

COPENHAGEN, Denmark, June 20, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today the initial safety and immunogenicity results from a randomized, double-blind, placebo-controlled Phase 3 clinical trial of a virus-like particle (VLP)-based chikungunya virus (CHIKV) vaccine candidate CHIKV VLP (PXVX0317) in healthy adults ≥65 years of age.

Key Points: 
  • COPENHAGEN, Denmark, June 20, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today the initial safety and immunogenicity results from a randomized, double-blind, placebo-controlled Phase 3 clinical trial of a virus-like particle (VLP)-based chikungunya virus (CHIKV) vaccine candidate CHIKV VLP (PXVX0317) in healthy adults ≥65 years of age.
  • Results from a second Phase 3 study evaluating the safety and immunogenicity of CHIKV VLP in healthy adolescents and adults 12 to 64 years old will report data during the third quarter of 2023.
  • A total of 413 participants were enrolled and randomized 1:1 to receive either a single intramuscular injection of CHIKV VLP or placebo.
  • They also match what has previously been reported for younger adults in an earlier Phase 2 study, including a fast onset of protection.

Valneva Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in The Lancet

Retrieved on: 
Tuesday, June 13, 2023
Biologics license application, Saint-Herblain, Vaccination, Public, Valneva SE, Chikungunya, Trial of the century, Euronext Paris, VLA, PDUFA, FDA, Health Canada, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BLA, Food, Pharmaceutical industry, Vaccine, Lancet

Saint-Herblain (France), June 13, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces that the Company’s pivotal Phase 3 data for its single-shot chikungunya vaccine candidate, VLA1553, have been published in The Lancet , the world’s leading peer-reviewed medical journal.

Key Points: 
  • Saint-Herblain (France), June 13, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces that the Company’s pivotal Phase 3 data for its single-shot chikungunya vaccine candidate, VLA1553, have been published in The Lancet , the world’s leading peer-reviewed medical journal.
  • This immunogenicity profile was similar in both younger and older adults, and 96% of participants maintained seroresponse six months after vaccination.
  • VLA1553 is currently the only chikungunya vaccine candidate worldwide for which regulatory review processes are underway.
  • If approved, VLA1553 could become the first licensed chikungunya vaccine available to address this unmet medical need.

Insect Repellent Active Ingredients Market worth $1.5 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, June 9, 2023
Prevalence, Chikungunya, Dry, National library, Chemical substance, Telephone numbers in Hungary, Dengue fever, S. C. Johnson & Son, Region, Virus, Coghlan, Malaria, Anticoagulant, Lyme disease, Infection, USD, Death, Insect, Bacteria, Rat, Bed bug, PCR, Skin, Pest control, Tick, Parasitism, Agriculture, WHO, Comparison of birth control methods, Disease, Pellet, Clothing, Biting, Quality of life, Zika virus, DEET, Canine vector-borne disease, Medicine, Beauty salon, Mouse, Cockroach, Application, ZIKV, Form, Powder, Godrej

CHICAGO, June 9, 2023 /PRNewswire/ -- The Insect Repellent Active Ingredients Market is estimated at USD 1.0  billion in 2023 and is projected to reach USD 1.5 billion by 2028, at a CAGR of 7.6% from 2023 to 2028 according to a report published by MarketsandMarkets™.

Key Points: 
  • CHICAGO, June 9, 2023 /PRNewswire/ -- The Insect Repellent Active Ingredients Market is estimated at USD 1.0  billion in 2023 and is projected to reach USD 1.5 billion by 2028, at a CAGR of 7.6% from 2023 to 2028 according to a report published by MarketsandMarkets™.
  • As people become more aware of the health risks associated with insect bites, the demand for insect repellent products, and consequently, their active ingredients, has increased.
  • The insect repellent active ingredients market industry has been studied in North America, Europe, Asia Pacific, South America and Rest of the World.
  • These diseases pose significant health risks to the population, leading to a greater demand for insect repellent products and active ingredients to protect against insect bites.

Insect Repellent Active Ingredients Market worth $1.5 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, June 9, 2023
Prevalence, Chikungunya, Dry, National library, Chemical substance, Telephone numbers in Hungary, Dengue fever, S. C. Johnson & Son, Region, Virus, Coghlan, Malaria, Anticoagulant, Lyme disease, Infection, USD, Death, Insect, Bacteria, Rat, Bed bug, PCR, Skin, Pest control, Tick, Parasitism, Agriculture, WHO, Comparison of birth control methods, Disease, Pellet, Clothing, Biting, Quality of life, Zika virus, DEET, Canine vector-borne disease, Medicine, Beauty salon, Mouse, Cockroach, Application, ZIKV, Form, Powder, Godrej

CHICAGO, June 9, 2023 /PRNewswire/ -- The Insect Repellent Active Ingredients Market is estimated at USD 1.0  billion in 2023 and is projected to reach USD 1.5 billion by 2028, at a CAGR of 7.6% from 2023 to 2028 according to a report published by MarketsandMarkets™.

Key Points: 
  • CHICAGO, June 9, 2023 /PRNewswire/ -- The Insect Repellent Active Ingredients Market is estimated at USD 1.0  billion in 2023 and is projected to reach USD 1.5 billion by 2028, at a CAGR of 7.6% from 2023 to 2028 according to a report published by MarketsandMarkets™.
  • As people become more aware of the health risks associated with insect bites, the demand for insect repellent products, and consequently, their active ingredients, has increased.
  • The insect repellent active ingredients market industry has been studied in North America, Europe, Asia Pacific, South America and Rest of the World.
  • These diseases pose significant health risks to the population, leading to a greater demand for insect repellent products and active ingredients to protect against insect bites.

Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June

Retrieved on: 
Wednesday, May 31, 2023
Vaccine, GSK, Infectious Diseases Society of America, Therapy, Saint-Herblain, EVP, Jefferies, Chikungunya, Infection, COVID, Teaching hospital, Goldman Sachs, Euronext Paris, Food and Drug Administration, VLA, BioMérieux, Webcast, FDA, Health Canada, Conference, Food, Pharmaceutical industry, Qiagen, Valneva SE

Valneva will also discuss its Phase 3 Lyme disease vaccine candidate (VLA15) and its currently commercialized vaccine products during the conferences.

Key Points: 
  • Valneva will also discuss its Phase 3 Lyme disease vaccine candidate (VLA15) and its currently commercialized vaccine products during the conferences.
  • Jefferies Healthcare Conference: Peter Buhler, Chief Financial Officer of Valneva will present on Wednesday, June 7, 2023, at 1.30pm ET.
  • A replay of the webcast will be available following the live events in the “Investor” section of the Valneva website at www.valneva.com .
  • Goldman Sachs Annual Global Healthcare Conference: The Company will be available for 1on1 investor meetings.

Valneva Files for Chikungunya Vaccine Authorization with Health Canada

Retrieved on: 
Tuesday, May 30, 2023
Epidemic, Biologics license application, Pan American Health Organization, Saint-Herblain, Vaccination, Priority, Coalition, European Medicines Agency, Valneva SE, CEPI, PAHO, Coalition for Epidemic Preparedness Innovations, Licensure, Chikungunya, Person, Trial of the century, Fast track (FDA), EMA, Euronext Paris, VLA, MD, Instituto Butantan, PDUFA, Ageing, FDA, Health Canada, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BLA, Food, Pharmaceutical industry, Vaccine

Saint-Herblain (France), May 30, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces the filing of a regulatory application with Health Canada for marketing approval of the Company’s single-shot chikungunya vaccine candidate, VLA1553, in persons aged 18 years and above.

Key Points: 
  • Saint-Herblain (France), May 30, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces the filing of a regulatory application with Health Canada for marketing approval of the Company’s single-shot chikungunya vaccine candidate, VLA1553, in persons aged 18 years and above.
  • If accepted, Health Canada will provide additional information on the potential approval timeline.
  • This is the second regulatory application for VLA1553 filed by Valneva, and the Company intends to make additional regulatory submissions in 2023.
  • VLA1553 is currently the only chikungunya vaccine candidate worldwide for which regulatory review processes are underway and, if approved, it could become the first licensed chikungunya vaccine available to address this unmet medical need.

Mosquito Joe® Urges Early Action for Mosquito Control and Prevention this Season

Retrieved on: 
Thursday, April 13, 2023
Neighborly, West Nile virus, Lyme disease, Education, Pest control, Mosquito-borne disease, Tick, IPM, Chikungunya, Zika virus, Snow, Associate, Centers for Disease Control and Prevention, DEET, EPA, Fever Dream, Risk, Personal protective equipment, Canine vector-borne disease, Water, Camping, Health, Environment, Disease, Malaria, Tea, Vaccine

VIRGINIA BEACH, Va., April 13, 2023 /PRNewswire/ -- Mosquito Joe®, a Neighborly® company, is taking the lead this season in early mosquito control and prevention, urging homeowners to take action against mosquitoes and ticks. With warmer winters in some regions across the country, peak mosquito season is fast approaching, and many areas will have a larger presence of bugs this year due to the accumulation of moisture and snow.

Key Points: 
  • VIRGINIA BEACH, Va., April 13, 2023 /PRNewswire/ -- Mosquito Joe ®, a Neighborly ® company, is taking the lead this season in early mosquito control and prevention, urging homeowners to take action against mosquitoes and ticks.
  • "With the recent moisture and snow accumulation, homeowners should take early action and protect themselves against the potential health risks posed by these pests."
  • Franchise locations across the US offer professional services that provide reliable and effective solutions for mosquito and tick control.
  • For more information about Mosquito Joe and how to take early action in pest control this year, visit MosquitoJoe.com.

Groundbreaking Partnership to Combat Dengue Mosquito in the Republic of the Marshall Islands Will Deploy Oxitec Friendly™ Aedes aegypti Solution

Retrieved on: 
Friday, March 31, 2023
RMI, Male, Partnership, Bee, Human services, Public, Yellow fever, Chikungunya, Centers for Disease Control and Prevention, Female, OXFORD, Government, Butterfly, CDC, Ministry, Notifiable disease, Republic, Fever Dream, Marshall Islands, Stockholm Environment Institute US Center, City, Ecosystem, United States Department of Health and Human Services, Vaccine, Zika fever, Pacific Ocean, Oxitec, Aedes, Ebeye Island

The Republic of the Marshall Islands has selected Oxitec's Friendly™ Aedes aegypti solution for a new pilot intervention to control the disease-spreading invasive Aedes aegypti mosquito.

Key Points: 
  • The Republic of the Marshall Islands has selected Oxitec's Friendly™ Aedes aegypti solution for a new pilot intervention to control the disease-spreading invasive Aedes aegypti mosquito.
  • Aedes aegypti has spread globally and is the primary vector of diseases such as dengue, Zika, chikungunya and yellow fever.
  • Deployments of the Friendly™ Aedes aegypti are planned to be conducted on Ebeye Island where, in 2019, a severe dengue outbreak forced a 'state of health emergency'.
  • Oxitec's CEO, Grey Frandsen, said, "We're honoured that our Friendly™ Aedes aegypti solution has been selected by the Ministry of Health of the Republic of the Marshall Islands for a groundbreaking new pilot program to address the invasive Aedes aegypti mosquito in the RMI.

Groundbreaking Partnership to Combat Dengue Mosquito in the Republic of the Marshall Islands Will Deploy Oxitec Friendly™ Aedes aegypti Solution

Retrieved on: 
Friday, March 31, 2023
RMI, Male, Partnership, Bee, Human services, Public, Yellow fever, Chikungunya, Centers for Disease Control and Prevention, Female, OXFORD, Government, Butterfly, CDC, Ministry, Notifiable disease, Republic, Fever Dream, Marshall Islands, Stockholm Environment Institute US Center, City, Ecosystem, United States Department of Health and Human Services, Vaccine, Zika fever, Pacific Ocean, Oxitec, Aedes, Ebeye Island

The Republic of the Marshall Islands has selected Oxitec's Friendly™ Aedes aegypti solution for a new pilot intervention to control the disease-spreading invasive Aedes aegypti mosquito.

Key Points: 
  • The Republic of the Marshall Islands has selected Oxitec's Friendly™ Aedes aegypti solution for a new pilot intervention to control the disease-spreading invasive Aedes aegypti mosquito.
  • Aedes aegypti has spread globally and is the primary vector of diseases such as dengue, Zika, chikungunya and yellow fever.
  • Deployments of the Friendly™ Aedes aegypti are planned to be conducted on Ebeye Island where, in 2019, a severe dengue outbreak forced a 'state of health emergency'.
  • Oxitec's CEO, Grey Frandsen, said, "We're honoured that our Friendly™ Aedes aegypti solution has been selected by the Ministry of Health of the Republic of the Marshall Islands for a groundbreaking new pilot program to address the invasive Aedes aegypti mosquito in the RMI.